Informations cliniques
La polyarthrite rhumatoïde (PR) se caractérise par des articulations douloureuses et gonflées, avec une limitation des mouvements et une destruction progressive des articulations. 0,5 à 1 % de la population mondiale est concernée, les femmes étant environ deux fois plus nombreuses que les hommes. La plupart des nouveaux cas sont constatés chez les femmes âgées de 55 à 64 ans et chez les hommes de 65 à 75 ans. La plupart des patients atteints de PR (environ 70 %) produisent des auto-anticorps dirigés contre les peptides citrullinés (ACPA), ce qui entraîne la formation de complexes immuns et la poursuite de l’inflammation articulaire.
Les auto-anticorps dans la PR apparaissent en moyenne 3 à 5 ans, parfois 15 ans avant les premiers symptômes articulaires. Les principaux auto-anticorps dans la PR pré-clinique sont les facteurs rhumatoïdes (FR) et les ACPA, pour la détection desquels on utilise principalement les peptides cycliques citrullinés (CCP) comme antigènes cibles, ainsi que la protéine Sa (vimentine citrullinée) et le peptide citrulliné énolase 1 (CEP-1). Les ACPA sont spécifiques à la PR et sont des indicateurs d’une évolution grave, érosive et destructrice. Lors du passage de la phase d’arthrite indifférenciée à la PR, les taux d’ACPA augmentent et restent élevés. Les ACPA ont une valeur prédictive élevée pour l’apparition d’une PR, leur détection favorise le diagnostic précoce.
Diagnostics
The determination of ACPA has been part of the RA classification criteria of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) since 2010. ACPA are determined in parallel to RF. According to the scoring system of the ACR/EULAR classification, a high ACPA or RF titer carries more weight for the classification of RA than a lower titer. Laboratory findings such as an increased erythrocyte sedimentation rate, increased C-reactive protein and the presence of RF and/or ACPA are indicative of RA Aletaha et al., Ann Rheum Dis (2010), 69:1580-1588).
Autoantibodies against CCP can be determined using ELISA and ChLIA. For the detection of ACPA, the second-generation CCP antigen (CCP2) is considered the gold standard. Test systems based on this antigen provide the highest sensitivity (80 %, with a specificity of 98%). Antibodies against CCP are mainly IgG class antibodies and are significantly more specific than RF, with a similar sensitivity. Anti-CCP antibodies are found in up to 60 % of RF-negative patients.
CEP-1 is another relevant autoantigen, which is present in approx. 60 % of anti-CCP-positive RA patients. The detection of antibodies against CEP-1 is highly specific for RA (specificity: 97.6 %) and therefore suited as a supplementary test for the confirmation of serological findings. Moreover, the detection of anti-CEP-1 supports risk stratification: Anti-CEP-1 antibodies are associated with an erosive disease course and with interstitial lung disease (Alunno et al., Rheumatology (2018) 57:850-855). Furthermore, anti-CEP-1 antibodies occur in a subtype of RA for which smoking and the HLA-DRB1 “shared epitope” alleles are the main risk factors (Mahdi et al., Nat Genet (2009) 41:1319-1324). Since anti-CEP-1 antibodies are directed against a target antigen which actually occurs in RA, their detection can provide insight into the cause and the pathogenesis of the disease.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ChLIA | IDS Calprotectin Control Set | 3 x 0.5 ml control 1/2 | Calprotectin |
2 concentration levels |
IS-AI260301 | ||
| ChLIA | CRP | immunoturbidimetric assay |
quantitative |
01 x 190 |
CPTXL-H00/IDS1 | ||
| ELISA | Anti-Sa ELISA (IgG) |
antigen-coated microplate wells |
citrullinated Sa antigen | 2/20/200 RU/ml | IgG |
48 x 02 |
EA 151a-4802 G |
| ELISA |
Anti-CCP ELISA (IgG) cyclic citrullinated peptides |
antigen-coated microplate wells |
highly purified synthetic CCP (second generation) |
1/5/20/100/ 200 RU/ml |
IgG |
96 x 01 |
EA 1505-9601 G |
| ELISA | Anti-CEP-1 ELISA (IgG) |
antigen-coated microplate wells |
citrullinated alpha-enolase peptide |
2/20/200 RU/ml | IgG |
96 x 01 |
EA 151b-9601 G |
| ELISA |
IgA Rheumatoid Factor ELISA (ab of class IgA against IgG) |
antigen-coated microplate wells |
IgG, human |
2/20/200 RU/ml | IgA |
96 x 01 |
EA 1814-9601 A |
| ELISA |
IgG Rheumatoid Factor ELISA (ab of class IgG against IgG) |
antigen-coated microplate wells |
IgG, goat |
2/20/200 RU/ml | IgG |
96 x 01 |
EA 1814-9601 G |
| ELISA |
IgM Rheumatoid Factor ELISA (ab of class IgM against IgG) |
antigen-coated microplate wells |
IgG, human |
2/20/200 RU/ml | IgM |
96 x 01 |
EA 1814-9601 M |
| ELISA |
CIC-C1q ELISA (IgG) circulating immune complexes |
antigen-coated microplate wells |
native, human C1q |
2/20/200 RU/ml | IgG |
96 x 01 |
EA 1818-9601 G |
| ELISA | Circulating Calprotectin ELISA |
antibody-coated microplate wells |
96 x 01 |
EQ 6831-9601 | |||
| ChLIA | CRP Medium Control | 1 x 2.0 ml Control M | C-reactive protein (CRP) |
1 concentration |
CPCON-0021 | ||
| ChLIA | CRP High Control | 1 x 2.0 ml Control H | C-reactive protein (CRP) |
1 concentration |
CPCOX-0021 | ||
| ChLIA | CRP Calibrator Set | 1 x 1.0 ml Calibrator 1/2/3/4/5 | C-reactive protein (CRP) |
5 concentrations |
CPREK-0001 | ||
| ChLIA | IDS CCP | antigenic coated magnetic particles | CCP |
quantitative |
100 x 01 |
IS-AI12011 | |
| ChLIA | IDS CCP Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-AI12301 | ||
| ChLIA | IDS Fluid Calprotectin | Antibody-coated magnetic particles | Calprotectin | quantitative |
100 x 01 |
IS-AI261001 | |
| ChLIA | IDS Fluid Calprotectin Calibrator Set | 2 x 0.5 ml calibrator 1/2/3/4/5 | Calprotectin |
5 concentrations |
IS-AI261201 | ||
| ChLIA | Anti-CCP ChLIA (IgG) | Antigen-coated magnetic particles | quantitative | IgG |
01 x 00 |
LA 1505-0100 G | |
| ChLIA | Control set Anti-CCP ChLIA (IgG) | 2 x 0.4 ml control 1/2 | IgG |
02 x 02 |
LR 1505-0160 G | ||
| ChLIA | Rheumatoid Factor Control Set | 3 x 1.5 ml Control 1/2 | human Rheumatoid Factor (RF) |
2 concentrations |
RFCOK-000/IDS1 | ||
| ChLIA | Rheumatoid Factor | colloidal gold particles | IgG specific for Rheumatoid Factor |
quantitative |
100 x 01 |
RFCOL-B00/IDS1 | |
| ChLIA | Rheumatoid Factor Control | 1 x 2.0 ml Control 1 | human Rheumatoid Factor (RF) |
1 concentration |
RFCON-002/IDS1 | ||
| ChLIA | Rheumatoid Factor Calibration Set | 1 x 1.5 ml Calibrator 1/2/3/4/5 | human Rheumatoid Factor (RF) |
5 concentrations |
RFREK-000/IDS1 | ||
| ChLIA |
Nu.Q® NETs H3.1 nucleosome |
Antibody-coated magnetic particles | H3.1 nucleosome |
quantitative |
100 x 01 |
2001-02-011 | |
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||